Jeffrey M. Rosen to receive 2022 William L. McGuire Memorial Lecture Award

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jeffrey M. Rosen will receive the William L. McGuire Memorial Lecture Award at the 2022 San Antonio Breast Cancer Symposium, to be held Dec. 6-10, 2022.

Rosen will present a lecture titled “Leveraging Preclinical Models for Translational Breast Cancer Research” during the symposium.

The William L. McGuire Memorial Lecture Award was established in 1992 to commemorate McGuire’s contributions to breast oncology. McGuire, along with Charles A. Coltman, founded SABCS in 1977.

Rosen is a distinguished service professor of molecular and cellular biology and the co-leader of the breast cancer program at the Dan L Duncan Comprehensive Cancer Center of Baylor College of Medicine.

Rosen is being recognized for his contributions to preclinical and translational breast cancer research, and for his commitment to transdisciplinary collaboration and mentoring of early-career scientists.

Throughout his 53-year career, Rosen has focused on understanding hormonal regulation of mammary gland development, tumorigenesis, and milk production; developing widely used animal models to study normal development and tumorigenesis of the breast; elucidating the mechanisms underlying self-renewal and differentiation of mammary stem cells and cancer stem cells; clarifying the roles of epithelial-to-mesenchymal transition in breast cancer metastasis and therapeutic resistance; and characterizing the tumor immune microenvironment associated with different subtypes of breast tumors.

Rosen joined the faculty at Baylor College of Medicine in 1973 and was a founding member of the Department of Cell Biology. While on sabbatical in the laboratory of George Stark, Rosen was involved in the early studies that elucidated the mechanisms of interferon action, which helped lead to the discovery of the JAK/STAT pathway. In addition, Rosen has mentored more than 100 graduate students, postdoctoral fellows, and junior faculty members.

Rosen was elected a Fellow of the American Academy of Arts and Sciences in 2015. He received the American Association for Cancer Research Distinguished Lectureship in Breast Cancer Research in 2017, the Susan G. Komen Brinker Basic Science Award in 2010, the Michael E. DeBakey, MD, Excellence in Research Award in 2004, and the Barbara & Corbin J. Robertson Jr. Presidential Award for Excellence in Education in 2002, among others.

Table of Contents

YOU MAY BE INTERESTED IN

Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.
For over 50 years, scientists have been on a quest to identify which malignant mutations within the tumor allow rogue cells to break away from the primary tumor and travel through the bloodstream and lymphatic system to metastasize throughout the body. Now, new research suggests an alternative mechanism has been overlooked—elusive mutations driving metastasis may not be developing within the twisted DNA of tumors themselves, but within the patient’s regular, inherited DNA. 
Novartis announced results from an updated analysis of the pivotal phase III NATALEE trial of Kisqali (ribociclib) that underscore the extended efficacy beyond the duration of treatment in combination with endocrine therapy. Results showed a sustained reduction in distant recurrence of 28.5% (HR=0.715; 95% CI 0.604-0.847; nominal P<0.0001), compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login